INF39 [866028-26-4]
Referencia HY-101868-5mg
embalaje : 5mg
Marca : MedChemExpress
| Descripciòn |
INF39 is an irreversible and noncytotoxic NLRP3 inhibitor. |
|
|---|---|---|
| IC50 & Target |
|
|
| In Vitro |
INF39 is able to significantly inhibit ATP- and nigericin-induced IL-1β release at 10 μM. INF39 reduces caspase-1 activation and pyroptosis in the macrophages. INF39 can block not only NLRP3 activation but also the NF-κB pathway. INF39 potentially reacts with Cys-SH residues in the active site of cysteine protease caspase-1, but does not directly target caspase-1 activity. INF39 is able to reduce the steady state (or basal) BRET signal of NLRP3 without affecting the viability of cells, meaning that it can interfere with the basal NLRP3 conformation. INF39 does not block the initial conformational changes suffered by NLRP3 upon sensing the decrease of intracellular K+; however, it affects a second step of NLRP3 conformational change that could be related with the ATPase activity of the receptor and be independent of the decrease of intracellular K+. INF39 reaches the intestinal epithelium without undergoing chemical modifications. After absorption into epithelial cells, it is likely to act locally at the mucosal epithelial level[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |

